ONE NUCLEUS STRENGTHENS BOARD WITH APPOINTMENT OF NEW DIRECTOR

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024

Life Sciences industry leader joins the region’s Life Science & Healthcare membership organisation
Cambridge, UK: 10 April 2024
A Supportive Membership Offer While You Plan Your Next Step
Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.
A new funded programme will support start-ups applying structural chemistry data, AI and machine learning to solve real-world scientific challenges
The Cambridge Crystallographic Data Centre (CCDC) today announced the launch of the CCDC Innovation Fund, a new seed funding programme designed to support emerging companies developing innovative solutions in structural chemistry.
Company Description
Scarlet Therapeutics is a biotechnology company developing transformative therapies. Building on more than a decade of world-renowned research in Bristol, UK, the team at Scarlet is pioneering unique technology to harness the potential of blood as medicine, positioning the company to become the global leader in the field of therapeutic red blood cells.
An exciting opportunity has become available for an experienced Senior Scientist to join our Protein Characterisation team in Slough. In this role, you will contribute to the analytical characterisation of therapeutic proteins, supporting the development of life-changing biologic medicines while working with advanced analytical technologies in a collaborative scientific environment.
OMass Therapeutics is a biotechnology company based in Oxford discovering medicines against highly- validated target ecosystems, such as membrane proteins or intracellular complexes. The company’s unique OdyssION™ technology platform comprises novel biochemistry techniques, next-generation native mass spectrometry, and custom chemistry. OMass is advancing a pipeline of small molecule therapeutics in rare diseases and immunological conditions, that target solute carriers, complex-bound proteins, and GPCRs.
Want to connect with University of Cambridge Talent? Drop by our office for an informal chat over tea or coffee on Thursday 13 August at 12:30 – 3:00pm!
Our SME Employer Coffee Drop-In Sessions are a chance to meet members of our friendly Employer Engagement team in an informal setting, ask questions and explore the different ways we can help you connect with Cambridge, whatever stage your business is at.